An Evaluation of the Effect of Community-based Pharmacist Intervention on Patients With Chronic Pain
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Pain
- Sponsor
- University of Waterloo
- Enrollment
- 19
- Locations
- 1
- Primary Endpoint
- Pain intensity change
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
This is a prospective, pre post, pilot cohort study to be conducted in patients with chronic pain, which is defined as pain that lasts beyond 3 months. To accomplish the primary and secondary objectives of the study, three phrases will be designed and completed during three months
Detailed Description
This study will evaluate the effectiveness of community-based pharmacist interventions on the quality of life of patients with chronic pain as determined by self-reported pain levels using an established scoring system. Participating pharmacists will enroll chronic pain patients from their normal practice to receive a consultation, which consists of an assessment of their current pain, a medication review, and education about their condition. Based on the information provided by the patient, the pharmacist will prepare a care plan, contact the patient's prescriber, and, in conjunction with the prescriber, implement the plan to help relieve their pain. Follow-up assessments will be done after 2 weeks, and 3 months.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 18 or older
- •Baseline average pain intensity using Brief Pain Inventory is 6 or higher
- •Ambulatory and able to attend the intervention
- •Complaining of pain for 3 months or longer
Exclusion Criteria
- •Patients with malignant or cancer pain
- •Patients who are unable to communicate in English
- •Non-ambulatory and unable to attend the intervention at the participating site
- •Unable to give informed consent.
Outcomes
Primary Outcomes
Pain intensity change
Time Frame: baseline, 2 weeks follow-up, 3 months follow-up
Pain intensity will be measured with Brief Pain Inventory pain intensity subscale, and will be measured 3 times in total
Secondary Outcomes
- Pain interference(baseline, 2 weeks follow-up, 3 months follow-up)
- Quality of life change(baseline, 3 months follow-up)